Minimising steroids in lupus nephritis - Will B cell depletion pave the way?

Lupus

Volumn 22, Issue 4, 2013, Pages 390-399

  Lightstone, L ^a,b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Lupus nephritis; rituximab; steroid avoidance

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STEROID; TACROLIMUS;

DRUG BIOAVAILABILITY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MONOTHERAPY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; DRUG DESIGN; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; ORGAN TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84875930842     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203313476155     Document Type: Review

References (58)

1. Hench PS. The effects of hormones and vitamins on rheumatoid arthritis with special reference to cortisone, hydrocortisone and corticotropin. Int Z Vitaminforsch Beih. 1952 ; 23: 259-274
2. Heller BI, Jacobson WE, Hammarsten JF. The effect of cortisone in glomerulonephritis and the nephropathy of disseminated lupus erythematosus. J Lab Clin Med. 1951 ; 37: 133-142
3. Costenbader KH, Desai A, Alarcon GS, et al. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum. 2011 ; 63: 1681-1688
4. Ginzler EM, Bollet AJ, Friedman EA. The natural history and response to therapy of lupus nephritis. Annu Rev Med. 1980 ; 31: 463-487
5. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004 ; 350: 971-980
6. Lightstone L. Lupus nephritis: where are we now?. Curr Opin Rheumatol. 2013 ; 22: 252-256
7. Bargman JM. How did cyclophosphamide become the drug of choice for lupus nephritis?. Nephrol Dial Transplant. 2009 ; 24: 381-384
8. Austin HA 3rd, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986 ; 314: 614-619
9. Houssiau FA, Vasconcelos C, D'Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2013 ; 69: 61-64
10. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002 ; 46: 2121-2131
11. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009 ; 20: 1103-1112
12. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005 ; 353: 2219-2228
13. Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000 ; 343: 1156-1162
14. Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011 ; 365: 1886-1895
15. Croca SC, Rodrigues T, Isenberg DA. Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology. 2011 ; 50: 1424-1430
16. Dorner T. Crossroads of B cell activation in autoimmunity: Rationale of targeting B cells. J Rheumatol Suppl. 2006 ; 77: 3-11
17. Sabahi R, Anolik JH. B-cell-targeted therapy for systemic lupus erythematosus. Drugs. 2006 ; 66: 1933-1948
18. Diaz-Lagares C, Croca S, Sangle S, et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts. Autoimmun Rev. 2012 ; 11: 357-364
19. Murray E, Perry M. Off-label use of rituximab in systemic lupus erythematosus: A systematic review. Clin Rheumatol. 2013 ; 29: 707-716
20. Ramos-Casals M, Soto MJ, Cuadrado MJ, et al. Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus. 2009 ; 18: 767-776
21. Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2013 ; 62: 2458-2466
22. Houssiau FA. Therapy of lupus nephritis: Lessons learned from clinical research and daily care of patients. Arthritis Res Ther. 2012 ; 14: 202-202
23. Mosca M, Tani C, Carli L, et al. Glucocorticoids in systemic lupus erythematosus. Clin Exp Rheumatol. 2011 ; 29: S126 - S129
24. Merrill JT. Ending the 50-year drought of FDA drug approval for SLE. Bull NYU Hosp Jt Dis. 2011 ; 69: 238-242
25. Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001 ; 135: 248-257
26. Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007 ; 66: 1560-1567
27. Urowitz MB, Bookman AA, Koehler BE, et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976 ; 60: 221-225
28. Nossent J, Cikes N, Kiss E, et al. Current causes of death in systemic lupus erythematosus in Europe, 2000-2004: Relation to disease activity and damage accrual. Lupus. 2007 ; 16: 309-317
29. Nossent J, Kiss E, Rozman B, et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus. 2013 ; 19: 949-956
30. Gladman DD, Urowitz MB, Rahman P, et al. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol. 2003 ; 30: 1955-1959
31. Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus. 2000 ; 9: 170-175
32. Petri M, Lakatta C, Magder L, et al. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analysis. Am J Med. 1994 ; 96: 254-259
33. Petri M, Genovese M. Incidence of and risk factors for hospitalizations in systemic lupus erythematosus: A prospective study of the Hopkins Lupus Cohort. J Rheumatol. 1992 ; 19: 1559-1565
34. Urowitz MB, Gladman DD, Ibanez D, et al. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res. 2012 ; 64: 132-137
35. Hill MN, Grossman RA, Feldman HI, et al. Changes in causes of death after renal transplantation, 1966 to 1987. Am J Kidney Dis. 1991 ; 17: 512-518
36. Hoitsma AJ, Reekers P, Kreeftenberg JG, et al. Treatment of acute rejection of cadaveric renal allografts with rabbit antithymocyte globulin. Transplantation. 1982 ; 33: 12-16
37. Streem SB, Novick AC, Braun WE, et al. Low-dose maintenance prednisone and antilymphoblast globulin for the treatment of acute rejection. A steroid-sparing approach to immunosuppressive therapy. Transplantation. 1983 ; 35: 420-424
38. Tejani A, Butt KM, Rajpoot D, et al. Strategies for optimizing growth in children with kidney transplants. Transplantation. 1989 ; 47: 229-233
39. Hricik DE. Steroid withdrawal in renal transplant recipients: Pro point of view. Transplant Proc. 1998 ; 30: 1380-1382
40. Cattaneo D, Perico N, Gaspari F, et al. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 2002 ; 62: 1060-1067
41. Vincenti F. Is complete avoidance of calcineurin inhibitors or steroids now possible? Importance of patient selection and choice of regimen. Transplant Proc. 2001 ; 33: 11S - 18S
42. Cole E, Landsberg D, Russell D, et al. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. Transplantation. 2001 ; 72: 845-850
43. Kode R, Fa K, Chowdhury S, et al. Basiliximab plus low-dose cyclosporin vs. OKT3 for induction immunosuppression following renal transplantation. Clin Transplant. 2003 ; 17: 369-376
44. Borrows R, Chan K, Loucaidou M, et al. Five years of steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil. Transplantation. 2006 ; 81: 125-128
45. Borrows R, Loucaidou M, Van Tromp J, et al. Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation. Am J Transplant. 2004 ; 4: 1845-1851
46. Kung SC, Parikh M, Fyfe B, et al. Simulect induction facilitates Neoral-based steroid-free immunosuppression in primary kidney transplant recipients. Transplant Proc. 2004 ; 36: 475S - 477S
47. Chan K, Taube D, Roufosse C, et al. Kidney transplantation with minimized maintenance: Alemtuzumab induction with tacrolimus monotherapy - an open label, randomized trial. Transplantation. 2011 ; 92: 774-780
48. Pepper R, Griffith M, Kirwan C, et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant. 2009 ; 24: 3717-3723
49. Condon MB, Ashby D, Pepper R, et al. Prospective observational single centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. in review.
50. Dall'Era M, Stone D, Levesque V, et al. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Arthritis Care Res. 2011 ; 63: 351-357
51. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012 ; 64: 1215-1226
52. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet. 2011 ; 377: 721-731
53. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011 ; 63: 3918-3930
54. Van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012 ; 71: 1343-1349
55. Lightstone L. The landscape after LUNAR: Rituximab's crater-filled path. Arthritis Rheum. 2012 ; 64: 962-965
56. Vital EM, Dass S, Buch MH, et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum. 2011 ; 63: 3038-3047
57. Ezeonyeji AN, Isenberg DA. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: A steroid-sparing regimen. Rheumatology (Oxford). 2012 ; 51: 476-481
58. Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: Alternative definitions of complete response support conflicting conclusions. Arthritis Rheum. 2012 ; 64: 3660-3665